comparemela.com

Latest Breaking News On - Marisa borgasano - Page 3 : comparemela.com

Alkermes plc: Alkermes Presents New Data From Psychiatry Portfolio at 2022 Congress of the Schizophrenia International Research Society

- Detailed Results Presented From ENLIGHTEN-Early Phase 3b Study of LYBALVI in Patients Early in Illness - DUBLIN, April 7, 2022 /PRNewswire/ Alkermes plc (Nasdaq: ALKS) today presented

New yorkUnited statesAlex braunCraig hopkinsonMarisa borgasanoAripiprazole lauroxilBehavioral health systemResearch databasesSchizophrenia international research societyResearch development at alkermesDepartment of psychiatryIcahn school of medicine at mount sinaiAlkermes incAlkermes pharma irelandResults presented fromEarly phase

Alkermes plc: Alkermes Announces Positive Topline Results From ENLIGHTEN-Early Phase 3b Study of LYBALVI in Patients Early in Illness

- LYBALVI Demonstrated Less Weight Gain Compared to Olanzapine in Patients With Schizophrenia, Schizophreniform Disorder or Bipolar I Disorder - DUBLIN, Feb. 8, 2022 /PRNewswire/ Alkermes

United statesCraig hopkinsonMarisa borgasanoFerrari gozziSandy coombsChristoph correllAmerican psychiatric associationNational comorbidity survey replicationResearch developmentExchange commissionAlkermes pharma irelandAlkermes incLess weight gain comparedPatients with schizophreniaSchizophreniform disorderBipolari disorder

Alkermes Announces Positive Topline Results From ENLIGHTEN-Early Phase 3b Study of LYBALVI® in Patients Early in Illness

/PRNewswire/ Alkermes plc (Nasdaq: ALKS) today announced positive topline results from ENLIGHTEN-Early, a phase 3b study that evaluated the effect of.

United statesCraig hopkinsonMarisa borgasanoFerrari gozziSandy coombsChristoph correllAmerican psychiatric associationNational comorbidity survey replicationResearch developmentExchange commissionAlkermes pharma irelandAlkermes incExecutive vice presidentChief medical officerMolecular medicineHofstra northwell school

Alkermes Announces Positive Topline Results From ENLIGHTEN-Early Phase 3b Study of LYBALVI® in Patients Early in Illness

/PRNewswire/ Alkermes plc (Nasdaq: ALKS) today announced positive topline results from ENLIGHTEN-Early, a phase 3b study that evaluated the effect of.

United statesCraig hopkinsonMarisa borgasanoFerrari gozziSandy coombsChristoph correllAmerican psychiatric associationNational comorbidity survey replicationResearch developmentExchange commissionAlkermes pharma irelandAlkermes incExecutive vice presidentChief medical officerMolecular medicineHofstra northwell school

Alkermes plc: New National Survey of People Living with Bipolar I Disorder Provides Insights Into Disease-Related Challenges and the Treatment Journey

- Respondents Reported Physical and Psychosocial Impacts of Living with Bipolar I Disorder and Side Effects of Medications Used to Treat the Disease - - More Than Half of Respondents Reported

United statesMichael pollockMarisa borgasanoSandy coombsSarah akermanKathy steinbergExchange commissionAffairs at alkermesBipolar support allianceAlkermes incNational comorbidity survey replicationReported physicalPsychosocial impactsBipolari disorderSide effectsMedications used

vimarsana © 2020. All Rights Reserved.